Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct 1:339:b3805.
doi: 10.1136/bmj.b3805.

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database

D Gunnell  1 , D Irvine, L Wise, C Davies, R M Martin
Affiliations

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database

D Gunnell et al. BMJ. .

Abstract

Objective: To determine whether varenicline, a recently licensed smoking cessation product, is associated with an increased risk of suicide and suicidal behaviour compared with alternative treatments bupropion and nicotine replacement therapy.

Design: Cohort study nested within the General Practice Research Database.

Setting: Primary care in the United Kingdom.

Participants: 80,660 men and women aged 18-95 years were prescribed a new course of a smoking cessation product between 1 September 2006 and 31 May 2008; the initial drugs prescribed during follow-up were nicotine replacement products (n=63 265), varenicline (n=10 973), and bupropion (n=6422).

Main outcome measures: Primary outcomes were fatal and non-fatal self harm, secondary outcomes were suicidal thoughts and depression, all investigated with Cox's proportional hazards models.

Results: There was no clear evidence that varenicline was associated with an increased risk of fatal (n=2) or non-fatal (n=166) self harm, although a twofold increased risk cannot be ruled out on the basis of the upper limit of the 95% confidence interval. Compared with nicotine replacement products, the hazard ratio for self harm among people prescribed varenicline was 1.12 (95% CI 0.67 to 1.88), and it was 1.17 (0.59 to 2.32) for people prescribed bupropion. There was no evidence that varenicline was associated with an increased risk of depression (n=2244) (hazard ratio 0.88 (0.77 to1.00)) or suicidal thoughts (n=37) (1.43 (0.53 to 3.85)).

Conclusion: Although a twofold increased risk of self harm with varenicline cannot be ruled out, these findings provide some reassurance concerning its association with suicidal behaviour.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DG is a member of the Pharmacovigilance Expert Advisory Group of the MHRA. DI, LW, and CD are employees of the MHRA. RMM is a member of Independent Scientific Advisory Committee for MHRA database research (ISAC).

Figures

None
Fig 1 Rate of suicide related adverse events reported for varenicline per million tablets prescribed in 2007-2008. (Data source MHRA yellow cards and data derived from IMS HEALTH Midas database)
See this image and copyright information in PMC

Comment in

References

    1. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Safety 2009;32:119-35. - PubMed
    1. Hughes JR. Smoking and suicide: a brief overview. Drug and Alcohol Dependence 2008;98:169-78. - PMC - PubMed
    1. Hays JT, Ebert JO. Varenicline for tobacco dependence. N Engl J Med 2008;359:2018-24. - PMC - PubMed
    1. Medicines and Healthcare products Regulatory Agency (MHRA). Varenicline: possible effects on driving; psychiatric illness. Drug Safety Update 2007;1:12.
    1. Hemmingsson T, Kriebel D. Smoking at age 18-20 and suicide during 26 years of follow-up-how can the association be explained? Int J Epidemiol 2003;32:1000-4. - PubMed

Publication types